摘要
目的:比较雷替曲塞联合奥沙利铂与FOLFOX4方案对晚期结直肠癌临床综合疗效及安全性。方法:选取笔者所在医院2016年12月-2017年10月收治的晚期结直肠癌患者104例为研究对象,将患者随机分为研究组和对照组,每组52例。对照组给予FOLFOX4方案治疗,研究组给予雷替曲塞联合奥沙利铂治疗。比较两组临床综合疗效、生存期、不良反应发生情况。结果:研究组总缓解率为23.08%,对照组总缓解率为26.92%,两组比较差异无统计学意义(P>0.05)。研究组无进展生存期和总生存期均长于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为28.85%,低于对照组的48.08%,差异有统计学意义(P<0.05)。结论:与FOLFOX4方案相比雷替曲塞联合奥沙利铂联合治疗晚期结直肠癌能够提高患者的生存期,降低患者不良反应发生率,具有较好的临床应用和推广价值。
Objective:To compare the clinical comprehensive efficacy and safety of Letetrexed combined with Oxaliplatin and FOLFOX4 regimen in advanced colorectal cancer.Method:From December 2016 to October 2017,104 patients with advanced colorectal cancer admitted in our hospital were selected as study subjects.They were randomly divided into the study group and the control group,with 52 cases in each group.The control group was treated with FOLFOX4 regimen.The study group was treated with Letetrexed and Oxaliplatin.The clinical comprehensive efficacy,survival period and adverse reactions of the two groups were compared.Result:The total remission rate of the study group was 23.08%,the total remission rate of the control group was 26.92%,there was no significant difference between the two groups(P>0.05).The progression free survival and total survival of the study group were both longer than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 28.85%,which was lower than 48.08%in the control group,and the difference was statistically significant(P<0.05).Conclusion:Compared with FOLFOX4 regimen,Letetrexed combined with Oxaliplatin can improve the survival period of patients with advanced colorectal cancer,reduce the incidence of adverse reactions.It has better clinical application and promotion value.
作者
钟俊斌
魏建昌
王强
杨平
胡石奇
李旺林
曹杰
ZHONG Junbin;WEI Jianchang;WANG Qiang;YANG Ping;HU Shiqi;LI Wanglin;CAO Jie(Guangzhou First People’s Hospital,Guangzhou 510180,China;不详)
出处
《中外医学研究》
2020年第19期21-23,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
广东省自然科学基金项目(2017A030311035)。
